

Jeffrey J Mollrem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7753580/publications.pdf>

Version: 2024-02-01

82
papers

4,208
citations

172207

29
h-index

110170

64
g-index

83
all docs

83
docs citations

83
times ranked

4157
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. <i>Nature Medicine</i> , 2000, 6, 1018-1023.	15.2	651
2	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. <i>Nature Medicine</i> , 2006, 12, 1160-1166.	15.2	536
3	Antithymocyte globulin for patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1997, 99, 699-705.	1.2	262
4	Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. <i>Blood</i> , 2009, 114, 1958-1967.	0.6	235
5	Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units. <i>Blood</i> , 1997, 90, 2529-2534.	0.6	216
6	Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes. <i>Annals of Internal Medicine</i> , 2002, 137, 156.	2.0	196
7	Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. <i>Journal of Clinical Investigation</i> , 2003, 111, 639-647.	3.9	189
8	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1555-64.	3.3	174
9	Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?. <i>Seminars in Hematology</i> , 2000, 37, 15-29.	1.8	148
10	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , 2019, 10, 254.	5.8	120
11	Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. <i>Cancer Research</i> , 2017, 77, 5374-5383.	0.4	118
12	An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. <i>Blood</i> , 2011, 117, 4262-4272.	0.6	105
13	Breast Cancer Cell Uptake of the Inflammatory Mediator Neutrophil Elastase Triggers an Anticancer Adaptive Immune Response. <i>Cancer Research</i> , 2012, 72, 3153-3162.	0.4	77
14	A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. <i>Cytotherapy</i> , 2016, 18, 985-994.	0.3	77
15	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1435-1443.	1.6	75
16	Immunotherapy of Hematologic Malignancy. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 331-349.	0.9	67
17	Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. <i>Journal of Clinical Investigation</i> , 2003, 111, 639-647.	3.9	65
18	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016, 128, 297-312.	0.6	54

#	ARTICLE	IF	CITATIONS
19	Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. <i>Current Opinion in Hematology</i> , 2002, 9, 503-508.	1.2	49
20	Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. <i>British Journal of Haematology</i> , 1996, 93, 606-612.	1.2	48
21	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia. <i>Blood</i> , 2004, 104, 259-259.	0.6	47
22	Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 10295-10305.	1.6	41
23	Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. <i>Journal of Immunology</i> , 2012, 189, 5476-5484.	0.4	37
24	The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1. <i>Journal of Immunotherapy</i> , 2012, 35, 309-320.	1.2	37
25	A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 247-257.	3.2	33
26	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0160004.	1.1	33
27	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	0.8	32
28	Vaccination for Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 13-18.	2.0	31
29	Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone. <i>Cancer Research</i> , 2017, 77, 3144-3150.	0.4	31
30	Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. <i>Leukemia</i> , 2017, 31, 234-237.	3.3	30
31	Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. <i>Journal of Immunology</i> , 2018, 201, 1389-1399.	0.4	30
32	PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal. <i>PLoS ONE</i> , 2010, 5, e11770.	1.1	29
33	Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. <i>Cytotherapy</i> , 2010, 12, 1056-1062.	0.3	27
34	Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 741-751.	2.0	25
35	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.	1.6	25
36	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. <i>Blood Advances</i> , 2018, 2, 2052-2062.	2.5	24

#	ARTICLE	IF	CITATIONS
37	Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. <i>Clinical Cancer Research</i> , 2019, 25, 2610-2620.	3.2	23
38	Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells.. <i>Blood</i> , 2006, 108, 3654-3654.	0.6	19
39	Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. <i>Frontiers in Immunology</i> , 2017, 8, 1975.	2.2	18
40	Vaccines as consolidation therapy for myeloid leukemia. <i>Expert Review of Hematology</i> , 2011, 4, 37-50.	1.0	17
41	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. <i>Blood</i> , 2011, 118, 2159-2169.	0.6	14
42	Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. <i>Cytotherapy</i> , 2018, 20, 1089-1101.	0.3	13
43	A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. <i>Frontiers in Immunology</i> , 2018, 9, 3153.	2.2	12
44	Targeting PR1 in myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 4280-4281.	0.8	12
45	The basis of T-cell-mediated immunity to chronic myelogenous leukemia. <i>Oncogene</i> , 2002, 21, 8668-8673.	2.6	9
46	PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. <i>Cytotherapy</i> , 2016, 18, 995-1001.	0.3	9
47	Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. <i>Leukemia</i> , 2020, 34, 1626-1636.	3.3	9
48	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 283-283.	0.6	9
49	Leukemia vaccines. <i>Current Oncology Reports</i> , 2001, 3, 193-200.	1.8	8
50	Ibrutinib Treatment Modulates T Cell Activation and Polarization in Immune Response. <i>Blood</i> , 2015, 126, 3435-3435.	0.6	8
51	Genomics as a Tool for Antigen Discovery in Allogeneic Stem Cell Transplantation: Identification of the Minor Antigen T4A through Donor/Patient Polymorphism Disparities. <i>Blood</i> , 2008, 112, 3907-3907.	0.6	8
52	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. <i>British Journal of Haematology</i> , 2000, 111, 18-29.	1.2	6
53	Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure.. <i>Blood</i> , 2006, 108, 312-312.	0.6	6
54	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. <i>Blood</i> , 2007, 110, 577-577.	0.6	5

#	ARTICLE	IF	CITATIONS
55	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	0.6	5
56	Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018, 24, 3386-3396.	3.2	4
57	Allogeneic Transplantation after Myeloablative Rituximab/BEAM \pm Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1347-1354.	2.0	4
58	Tumor-Associated Antigens. , 2019, , 107-125.		3
59	Fidelity of peripheral blood for monitoring genomics and tumor immune microenvironment in myelodysplastic syndromes. <i>EJHaem</i> , 2020, 1, 552-557.	0.4	3
60	Understanding and Enhancing the Graft-Versus-Leukemia Effect After Hematopoietic Stem Cell Transplantation. <i>Cancer Treatment and Research</i> , 2009, 144, 187-208.	0.2	3
61	Preparing Basic and Translational Grant Proposals: Thoughts from the Trenches. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 181-184.	0.9	2
62	Soluble Inflammatory Mediators Proteinase-3 and Neutrophil Elastase Are Targeted by PR1-Specific Immunotherapy After Cellular Uptake and Cross Presentation of PR1 Peptide by Breast Cancer Cells. <i>Blood</i> , 2010, 116, 2089-2089.	0.6	2
63	Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. <i>Cytotherapy</i> , 2021, 23, 793-798.	0.3	1
64	PAND: A Distribution to Identify Functional Linkage from Networks with Preferential Attachment Property. <i>PLoS ONE</i> , 2015, 10, e0127968.	1.1	1
65	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. <i>Blood</i> , 2008, 112, 5440-5440.	0.6	1
66	Mitochondrial DNA (mtDNA) Sequence Heterogeneity among and within Single Human CD34 Cells, T Cells, B Cells and Granulocytes.. <i>Blood</i> , 2004, 104, 3217-3217.	0.6	0
67	Antigen Cross-Presentation Allows the PR1 Leukemia-Associated Antigen To Be Processed from Both Proteinase 3 and Neutrophil Elastase to Prime T Cells.. <i>Blood</i> , 2004, 104, 3245-3245.	0.6	0
68	High Avidity Cyclin E1-Derived Peptide-Specific CTL Kill Lymphoid Leukemia Cells and Cross-Recognize a Homologous Cyclin E2-Derived Peptide.. <i>Blood</i> , 2004, 104, 4498-4498.	0.6	0
69	Pre-Existing Anti-GM-CSF Autoantibodies in Patients with AML, CML and MDS Are Associated with Compromised Immune Response to PR1 Peptide Vaccination.. <i>Blood</i> , 2005, 106, 3257-3257.	0.6	0
70	Two Cyclin-Dependent Kinase Derived Peptides Are Potential Leukemia-Associated-Antigens Able To Eradicate Acute Myeloid Leukemia Cells after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 3103-3103.	0.6	0
71	Aberrantly Expressed Neutrophil Elastase (ELA2) Cleaves Cyclin E (CCNE) in the Nucleus and Cytoplasm of Acute Lymphocytic Leukemia Yielding Novel Leukemia-Associated Antigens.. <i>Blood</i> , 2006, 108, 4429-4429.	0.6	0
72	T-Cell Autoimmunity May Contribute to Neutropenia in a Patient with Cyclic Neutropenia (CN) and Double De-Novo Mutations in Gfi-1.. <i>Blood</i> , 2007, 110, 3298-3298.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Aberrant Subcellular Localization of Azurophil Granule Proteins in Myeloid Leukemia Favors Peptide Antigen Presentation on MHC-I and Susceptibility to Killing by Cytotoxic T Lymphocytes.. Blood, 2007, 110, 4900-4900.	0.6	0
74	Direct Visualization of PR1/HLA-A2 on the Membrane of HLAA2+ CD13+CD33+ Myeloid Leukemia Blasts by a Novel Monoclonal Antibody. Blood, 2008, 112, 2545-2545.	0.6	0
75	Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. Blood, 2008, 112, 719-719.	0.6	0
76	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	0.6	0
77	Breaking Immune Tolerance to Granule Proteases with Full-Length Antigen Vaccine in Humanized Transgenic Mice Reveals Alternative Antigen Processing and Immunodominance Hierarchy Applicable to Clinical Immunotherapy.. Blood, 2009, 114, 2054-2054.	0.6	0
78	LFA-1 Regulates CD8 + T Cell Activation and Immune Signal Network.. Blood, 2009, 114, 1641-1641.	0.6	0
79	Cellular Uptake of Soluble Neutrophil Elastase Increases Cyclin E (CCNE) Isoform Expression and Significantly Augments Susceptibility of Breast Cancer Cells to Cytolysis by CCNE-Specific Cytotoxic T Lymphocytes. Blood, 2010, 116, 2090-2090.	0.6	0
80	PML and PMLRAR1± Interact with Fas to Regulate Fas-Mediated Apoptosis In Vivo. Blood, 2011, 118, 2451-2451.	0.6	0
81	A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia. Blood, 2011, 118, 2986-2986.	0.6	0
82	Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade. Blood, 2020, 136, 4-4.	0.6	0